Speech-Language Pathologists in Englewood, FL Accepting Medicare
7 Speech-Language Pathologists found. Showing 1 - 7
 Katherine Forsman, MSP, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 386 Firethorn Ave, Englewood, FL 34223 Phone: 941-223-3782 |
Tara Maria Cortopassi, M.A. BCBA Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 338 Pine Glen Ct, Englewood, FL 34223 Phone: 941-587-4919 |
Karen Comeau, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 9271 Pine Cove Rd, Englewood, FL 34224 Phone: 978-852-3553 |
Mary Walker, SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: Legacy Healthcare / Heritage Oaks Of Englewood, 7374 San Casa Dr, Englewood, FL 34224 Phone: 941-698-2620 |
Mrs. Theresa Maria Miers-pandolfi, M.S.-SLP-CCC Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 325 Pine Glen Ct, Englewood, FL 34223 Phone: 941-473-0564 |
Lisa Ann Gorski, MS Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1858 Neptune Dr, Englewood, FL 34223 Phone: 414-750-7036 |
Ms. Cathy Lynne Pintwala Yates, M.S. SLP DOE CERTIFI Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 7455 San Casa Dr, Englewood, FL 34224 Phone: 843-504-9047 |
News Archive
Research: Heavy drinkers, illegal drug users downplay their consumption levels compared to others
Heavy drinkers and users of illegal drugs downplay their relative levels of consumption, when comparing themselves to others, reveals research by the London School of Economics and Political Science and South London and Maudsley NHS Foundation Trust.
Research shows smoking and obesity together may pose triple health threat
Millions of people who are obese and smoke tobacco may face additional health problems — including their responses to common prescription medicines — that extend beyond the well-known links with cancer, heart attacks and stroke, according to a report presented here today.
New results reinforce COPAXONE 40 mg/mL as safe and effective for RMS patients
Teva Pharmaceutical Industries Ltd., today announced up to 7-year efficacy, safety and tolerability results from the Glatiramer Acetate Low-Frequency Administration (GALA) open-label extension study of COPAXONE (glatiramer acetate injection) 40 mg/mL administered subcutaneously three-times-a-week for the treatment of relapsing forms of multiple sclerosis (RMS).
Long waits and long odds for those who need social security disability
By the time Stephenie Hashmi was in her mid-20s, she had achieved a lifelong dream — she was the charge nurse of one of Kansas City's largest intensive care units. But even as she cared for patients, she realized that something was off with her own health.
› Verified 7 days ago
Physical Therapists
Chiropractors
Optometrists
Speech-Language Pathologists
Audiologists
Podiatrists
Occupational Therapists